Genmab — December 2022
-
12 måneders kursmål
-
Jeg tror de har lavet en fejl
-
Tak GB.
-
Gode jobtal og markedet falder…
-
-
Dec 3 (Reuters) - Johnson & Johnson (JNJ.N) unit Janssen Global Services said on Saturday that it does not intend to make an offer for biotech company Horizon Therapeutics Plc https://www.reuters.com/markets/deals/jj-unit-says-does-not-intend-bid-horizon-therapeutics-2022-12-03/
-
Ang Orega må det næsten være denne der står på deres hjemmeside: Novel target.
Improving response to anti-PD1 therapy.
We have discovered a novel and potent regulator of anti-PD1 therapy in syngeneic mouse models harboring resistance to PD-1 immune checkpoint inhibitor. Neutralization of this target markedly improves the efficacy of anti-PD-1 mAb therapy by increasing the response rates and by increasing the rate of complete vs partial responses, which results in improved survival. -
Tak for info Peter12
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind